ES2871100T3 - Cebado in vivo de linfocitos citolíticos naturales - Google Patents

Cebado in vivo de linfocitos citolíticos naturales Download PDF

Info

Publication number
ES2871100T3
ES2871100T3 ES16847576T ES16847576T ES2871100T3 ES 2871100 T3 ES2871100 T3 ES 2871100T3 ES 16847576 T ES16847576 T ES 16847576T ES 16847576 T ES16847576 T ES 16847576T ES 2871100 T3 ES2871100 T3 ES 2871100T3
Authority
ES
Spain
Prior art keywords
cells
cell
priming
preparation
ptcp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16847576T
Other languages
English (en)
Spanish (es)
Inventor
Raymond J Tesi
David Moss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immune Ventures LLC
Original Assignee
Immune Ventures LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Ventures LLC filed Critical Immune Ventures LLC
Priority claimed from PCT/US2016/061835 external-priority patent/WO2017049327A2/en
Application granted granted Critical
Publication of ES2871100T3 publication Critical patent/ES2871100T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ES16847576T 2015-12-07 2016-11-14 Cebado in vivo de linfocitos citolíticos naturales Active ES2871100T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562263951P 2015-12-07 2015-12-07
PCT/US2016/061835 WO2017049327A2 (en) 2015-09-16 2016-11-14 In vivo priming of natural killer cells

Publications (1)

Publication Number Publication Date
ES2871100T3 true ES2871100T3 (es) 2021-10-28

Family

ID=63681977

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16847576T Active ES2871100T3 (es) 2015-12-07 2016-11-14 Cebado in vivo de linfocitos citolíticos naturales

Country Status (3)

Country Link
JP (1) JP6850297B2 (ja)
DK (1) DK3349769T3 (ja)
ES (1) ES2871100T3 (ja)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1863905T3 (pl) * 2005-03-17 2016-07-29 Ucl Business Plc Sposób aktywacji naturalnych komórek zabójców preparatami komórek guza in vitro
EP2451942A1 (en) * 2009-07-10 2012-05-16 Mark Lowdell Preserved compositions of activated nk cells and methods of using the same
WO2013132256A1 (en) * 2012-03-07 2013-09-12 Ucl Business Plc Compositions and methods for treating viral-mediated infection and disease in immunocompromised individuals

Also Published As

Publication number Publication date
JP2018528276A (ja) 2018-09-27
JP6850297B2 (ja) 2021-03-31
DK3349769T3 (da) 2021-03-08

Similar Documents

Publication Publication Date Title
CN106659742A (zh) 表达免疫应答刺激细胞因子以吸引和/或激活免疫细胞的基因修饰间充质干细胞
JP2019516754A (ja) 癌を処置するための方法及び組成物
Kabir et al. Immunotherapy for medulloblastoma: current perspectives
AU2016259020A1 (en) Dendritic cell immunotherapy
Marotel et al. The two-faces of NK cells in oncolytic virotherapy
AU2018203469B2 (en) In vivo priming of natural killer cells
WO2019158955A1 (en) Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids
Dyer et al. Turning cold tumours hot: oncolytic virotherapy gets up close and personal with other therapeutics at the 11th Oncolytic Virus Conference
Elert Calling cells to arms.
EP3940063A2 (en) Method for the expansion and differentiation of t lymphocytes and nk cells in adoptive transfer therapies
Eisenstein et al. Immune cells: More than simple carriers for systemic delivery of oncolytic viruses
US20200397824A1 (en) In vivo priming of natural killer cells
ES2871100T3 (es) Cebado in vivo de linfocitos citolíticos naturales
Smith et al. Immunotherapy in cancer treatment
KR102623065B1 (ko) 자연 살해 세포의 생체 내 프라이밍
ES2942485T3 (es) Tratamiento de la fiebre hemorrágica vírica con células NK-92
ES2965059T3 (es) Monocitos que expresan p21 para la terapia celular del cáncer
US20240001142A1 (en) Induction by low dose radiation of cancer cell targets for cell-based or small molecule therapy
Kerzel L’IFN-alpha secreto da macrofagi ingegnerizzati in vivo riduce le metastasi al fegato e induce l’attivazione di processi contro regolatori che ne limitano l’efficacia
KR20220081360A (ko) 유전적으로 변형된 자가 t-세포 면역요법을 사용하는 치료 방법
Pokrovska et al. Turning cold tumours hot: oncolytic virotherapy gets up close and personal with other therapeutics at the 11th Oncolytic Virus Conference
Sinkovics et al. Will the Human Cerebral Cortex Subdue the Oncogenome?
WO2009075556A1 (es) Procedimiento para sensibilizar células y el uso de las mismas para tratamiento de tumores
Arceci Myeloid Leukemias-Current and Future Approaches to Targeted and Individualized Therapies